[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-[5-(1-ethoxy-vinyl)-2-methoxymethyl-6-methyl-pyrimidin-4-yl]-amine | 215437-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-[5-(1-ethoxy-vinyl)-2-methoxymethyl-6-methyl-pyrimidin-4-yl]-amine
• 英文别名: N-[[4-[2-(2-tert-butyltetrazol-5-yl)phenyl]phenyl]methyl]-5-(1-ethoxyethenyl)-2-(methoxymethyl)-6-methylpyrimidin-4-amine
• CAS: 215437-35-7
• 化学式: C₂₉H₃₅N₇O₂
• 分子量: 513.643
• InChiKey: FDTLTHOLYKRBQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  99.9
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  [2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-[5-(1-ethoxy-vinyl)-2-methoxymethyl-6-methyl-pyrimidin-4-yl]-amine 在 盐酸 、 三溴化硼 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 8-[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5-hydroxy-2-hydroxymethyl-4-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  Metabolites of the Angiotensin II Antagonist Tasosartan:  The Importance of a Second Acidic Group

  摘要：

  Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT(1) receptor binding.

  DOI：

  10.1021/jm970690q
• 作为产物：
  描述：

  2-(methoxymethyl)-6-methylpyrimidin-4(3H)-one 在 potassium fluoride 、 sodium hydroxide 、 copper(l) iodide 、 四(三苯基膦)钯 、 tris-(dibenzylideneacetone)dipalladium(0) 、 碘 、 碳酸氢钠 、 lithium chloride 、 三氯氧磷 作用下， 以 甲苯 、 正丁醇 为溶剂， 反应 91.83h， 生成 [2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-[5-(1-ethoxy-vinyl)-2-methoxymethyl-6-methyl-pyrimidin-4-yl]-amine
  参考文献：
  名称：

  Metabolites of the Angiotensin II Antagonist Tasosartan:  The Importance of a Second Acidic Group

  摘要：

  Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT(1) receptor binding.

  DOI：

  10.1021/jm970690q

文献信息

• Metabolites of the Angiotensin II Antagonist Tasosartan:  The Importance of a Second Acidic Group
  作者：John W. Ellingboe、Michael D. Collini、Dominick Quagliato、James Chen、Madelene Antane、Jean Schmid、Dale Hartupee、Valerie White、C. Hyung Park、Tarak Tanikella、Jehan F. Bagli

  DOI：10.1021/jm970690q

  日期：1998.10.1

  Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT(1) receptor binding.